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Clinical effectiveness of a sedation protocol
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Lee P Skrupky1*, Anne M Drewry2, Brian Wessman2,3, R Ryan Field4, Richard E Fagley5, Linda Varghese6, Angela Lieu7,
Joshua Olatunde8, Scott T Micek9, Marin H Kollef10 and Walter A Boyle2
Abstract
Introduction: Randomized controlled trials suggest clinical outcomes may be improved with dexmedetomidine
as compared with benzodiazepines; however, further study and validation are needed. The objective of this study
was to determine the clinical effectiveness of a sedation protocol minimizing benzodiazepine use in favor of early
dexmedetomidine.
Methods: We conducted a before-after study including adult surgical and medical intensive care unit (ICU) patients
requiring mechanical ventilation and continuous sedation for at least 24 hours. The before phase included consecutive
patients admitted between 1 April 2011 and 31 August 31 2011. Subsequently, the protocol was modified to minimize
use of benzodiazepines in favor of early dexmedetomidine through a multidisciplinary approach, and staff education
was provided. The after phase included consecutive eligible patients between 1 May 2012 and 31 October 2012.
Results: A total of 199 patients were included, with 97 patients in the before phase and 102 in the after phase.
Baseline characteristics were well balanced between groups. Use of midazolam as initial sedation (58% versus 27%,
P <0.0001) or at any point during the ICU stay (76% versus 48%, P <0.0001) was significantly reduced in the after
phase. Dexmedetomidine use as initial sedation (2% versus 39%, P <0.0001) or at any point during the ICU stay
(39% versus 82%, P <0.0001) significantly increased. Both the prevalence (81% versus 93%, P =0.013) and median
percentage of days with delirium (55% (interquartile range (IQR), 18 to 83) versus 71% (IQR, 45 to 100), P =0.001)
were increased in the after phase. The median duration of mechanical ventilation was significantly reduced in the
after phase (110 (IQR, 59 to 192) hours versus 74.5 (IQR, 42 to 148) hours, P =0.029), and significantly fewer patients
required tracheostomy (20% versus 9%, P =0.040). The median ICU length of stay was 8 (IQR, 4 to 12) days in the
before phase and 6 (IQR, 3 to 11) days in the after phase (P =0.252).
Conclusions: Implementing a sedation protocol that targeted light sedation and reduced benzodiazepine use led
to significant improvements in the duration of mechanical ventilation and the requirement for tracheostomy,
despite increases in the prevalence and duration of ICU delirium.
Introduction
Pain, agitation and delirium are common occurrences in
critically ill patients, with potential untoward conse-
quences, and they often necessitate treatment with anal-
gesic, sedative and antipsychotic medications. Over the
last 15 years, considerable evidence has accumulated
demonstrating that both choice of agent and how we use
these drugs can significantly impact clinically relevant
patient outcomes. This, in turn, has influenced recent
pain, agitation and delirium guidelines [1]. With respect
to the use of sedatives, guidelines recommend targeting
light levels of sedation, daily interruption of sedation,
use of a valid and reliable sedation assessment tool and
optimizing sedation practices with a multidisciplinary
approach to education, protocol development and clin-
ical practice. Different from previous recommendations
[2], these guidelines suggest a shift away from benzo-
diazepines as the mainstay of therapy in favor of non-
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benzodiazepine alternatives, including dexmedetomidine
or propofol.
Some studies have shown that, compared with benzo-
diazepines, dexmedetomidine may reduce the prevalence
of coma and/or delirium and increase days free of delir-
ium [3,4]. However, some researchers have reported con-
flicting results of randomized controlled trials in which
delirium was assessed using less rigorous, unvalidated
criteria [5,6]. Two randomized controlled trials have also
demonstrated a reduced duration of mechanical ventila-
tion compared with a continuous infusion of midazolam
[4,6]. The utility of dexmedetomidine may be limited,
however, by increased incidences of hypotension and
bradycardia, limited ability to achieve deep sedation
(when indicated) and higher drug cost. Propofol has also
been shown to reduce the duration of mechanical venti-
lation compared with benzodiazepines [7], whereas the
impact on delirium is not well described. Unique con-
cerns with regard to propofol include hypertriglyc-
eridemia, pancreatitis and propofol infusion syndrome,
in addition to the potential for hypotension and respira-
tory depression.
As a result of many sedative-specific issues that may
limit appropriateness or tolerance in certain patient pop-
ulations, it is often necessary to have multiple agents
available for use when managing patients in the intensive
care unit (ICU) with a broad array of acute and chronic
disease states. It therefore becomes less clear how to
apply the findings of randomized controlled trials in
clinical practice and to determine how effective such
changes might be in this context. Given the potential
benefits of dexmedetomidine as compared with benzodi-
azepines, we sought to assess the clinical effectiveness of
modifying our sedation protocol to minimize benzodi-
azepine use in favor of increased early dexmedetomidine




We conducted a before-after study to assess the clinical
effectiveness of a sedation protocol minimizing benzodi-
azepines and favoring early use of dexmedetomidine.
The study was approved by the Washington University
in St Louis Human Research Protection Office, and waiver
of consent was granted.
Study setting and patient population
This study was conducted at Barnes-Jewish Hospital, a
1,200-bed academic medical center in St Louis, MO, USA.
Patients were included if they were mechanically venti-
lated in the surgical ICU (SICU) or medical ICU (MICU)
and required continuous sedation (midazolam, propofol
or dexmedetomidine) for at least 24 hours. Exclusion
criteria included age less than 18 years, intubation at
an outside hospital with prior sedation for >24 hours,
need for neuromuscular blockade, norepinephrine in-
fusion at a rate >10 μg/min (or 0.15 μg/kg/min) or
use of multiple vasopressors continuously for the ini-
tial 24 hours of mechanical ventilation, heart rate <50
beats/min in the 24 hours preceding initiation of con-
tinuous sedation, tracheostomy placement prior to
hospital admission, history of dementia, acute neuro-
logic injury (acute stroke, seizure or severe traumatic
brain injury) or death within 72 hours of intubation.
In the before phase, consecutive eligible patients were
enrolled between 1 April 2011 and 31 August 2011. Sub-
sequently, the sedation protocol was modified through a
multidisciplinary team approach, with the goal of min-
imizing use of benzodiazepine infusions and favoring
early use of dexmedetomidine. Physician and nursing
staff education was provided that emphasized optimizing
analgesia prior to initiating sedation, targeting light sed-
ation, using continuous sedation only when absolutely
necessary, minimizing benzodiazepine use, proper sedative
selection based on patient characteristics, and review of
the supporting evidence. The new sedation protocol was
implemented on 1 April 2012. The after phase was initi-
ated 1 month later to allow for implementation of the new
protocol and included consecutive eligible patients be-
tween 1 May 2012 and 31 October 2012.
Sedation-related practices and protocol
The MICU and SICU both use a nursing-directed sed-
ation protocol whereby the bedside nurses titrate sedatives
and analgesics to meet patient-specific goals for level of
sedation and pain management, as delineated by the ICU
team. In both ICUs, the level of sedation was assessed by
the bedside nurse with the Richmond Agitation–Sedation
Scale (RASS) and documented at least every 4 hours and
as needed for patients requiring mechanical ventilation.
The goal level of sedation in both phases was a RASS of 0
to −2, unless an alternative goal was deemed necessary by
the ICU team. In the before phase, the predominant seda-
tive used as a continuous infusion was midazolam, al-
though propofol and dexmedetomidine were permitted
according to physician discretion. Through a multidiscip-
linary approach, the sedation protocol was subsequently
modified. The only significant change in the scope or
structure of the protocol was to recommend dexmedeto-
midine as the preferred sedative in the absence of patient
characteristics that would predict intolerance or for which
another sedative might be most appropriate. Specifically,
the protocol recommended that dexmedetomidine not be
used if any of the following were present: traumatic brain
injury, acute and/or uncontrolled seizures, norepinephrine
dose >10 μg/min (or 0.15 μg/kg/min), requirement
for multiple vasopressors and/or inotropic support, heart
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rate <50 beats/min during the last 24 hours, sick sinus
syndrome, second- or third-degree heart block with no in-
ternal pacer, or treatment with continuous neuromuscular
blockade. The recommended initial dose of dexmedetomi-
dine was 0.5 μg/kg/hr, and a range of 0.2 to 1.5 μg/kg/hr
was allowed. Bolus doses of dexmedetomidine were
not recommended. Propofol and midazolam were also
allowed in the after phase according to physician dis-
cretion. In both phases, bolus doses of midazolam were
administered as needed for the management of break-
through agitation.
Pain was assessed using a visual analogue scale or the
Wong-Baker FACES Pain Scale for patients who were
able to communicate a response or via an institution-
specific non-communicative pain scale for those unable
to respond. The non-communicative pain scale assesses
facial expression, motor activity, patient vocalizations,
caregiver rating of pain, and changes in patient behavior.
The pain scale ratings were not collected as a data point.
The primary treatment modality for pain in both phases
was a fentanyl infusion and/or boluses as needed, ac-
cording the ICU team’s discretion.
Prior to the before phase, bedside nurses were trained
to perform the Confusion Assessment Method for the
ICU (CAM-ICU) via an online education module and
additional one-to-one instruction at the bedside was
provided by clinical nurse specialists dedicated to each
ICU. The CAM-ICU assessments were performed twice
daily, at approximately 7:00 AM and 7:00 PM, and docu-
mented accordingly. It was not required that sedation be
stopped for the evaluation, and all assessments for pa-
tients at a RASS of −3 and higher were included, con-
sistent with the practice in which the CAM-ICU was
validated. The delirium treatment section of the protocol
was the same in both the before and after phases and pro-
vided the option for scheduled and/or as needed intraven-
ous haloperidol to manage hyperactive delirium, defined
as a positive CAM-ICU with a RASS of +3 or +4. Alterna-
tive antipsychotic agents were also permitted at the discre-
tion of the ICU team.
In both ICUs, a daily spontaneous breathing trial proto-
col was used to facilitate liberation from the ventilator. In
addition, spontaneous awakening was practiced in the
SICU by protocol, whereas sedative interruption was per-
formed according to physician order in the MICU.
Data collection and definitions
Patients were identified for potential inclusion via daily
review of the SICU and MICU census Monday through
Friday by clinical pharmacists. Data was then retrieved
retrospectively via a combination of electronic query of
the pharmacy informatics database and manual chart re-
view. Data points collected included baseline demograph-
ics and comorbidities; reasons for requiring mechanical
ventilation and ICU admission (assessed by intensivists);
modified Acute Physiology and Chronic Health Evaluation
(APACHE) II score (excluding neurologic assessment);
opioid, sedative and antipsychotic use; all CAM-ICU as-
sessments during the ICU stay (up to a maximum of
14 days); all RASS assessments during the period of mech-
anical ventilation (up to a maximum of 14 days); use of
vasopressors and inotropes; and relevant clinical out-
comes, including duration of mechanical ventilation, need
for reintubation or tracheostomy, and ICU and hospital
lengths of stay.
The primary outcomes were the prevalence of delirium
and duration of mechanical ventilation. Criteria for delir-
ium were met when patients had a RASS of −3 or higher
and a concomitant positive CAM-ICU assessment. Pa-
tients were considered liberated from the mechanical
ventilator after removal of the endotracheal tube or after
24 hours of continuous tracheostomy collar in those
patients requiring tracheostomy. The occurrence of dex-
medetomidine failure leading to drug discontinuation was
also assessed via manual chart review, and the reason for
failure was categorized as inability to achieve RASS goal,
hypotension, or bradycardia.
Statistical analysis
A power analysis was performed a priori to determine
the minimum sample size necessary to detect clinic-
ally relevant reductions in the prevalence of delirium
and the duration of mechanical ventilation that were
consistent with results from previous randomized con-
trolled trials [4,6]. The baseline prevalence of delirium and
duration of mechanical ventilation were estimated based
on a retrospective database that included 73 SICU
and MICU patients from Barnes-Jewish Hospital meeting
the same inclusion criteria. The observed prevalence of
delirium was 85%, and mean duration of mechanical ven-
tilation was 138 (±95) hours. In order to detect a 20% re-
duction in the prevalence of delirium, 75 patients in each
group were required at a power of 80% and an α level of
0.05. At the same power and α levels, 100 patients in each
group were required to identify a 38-hour reduction in the
duration of mechanical ventilation.
All statistical analyses were performed using SAS
version 9.3 software (SAS Institute, Cary, NC, USA). Cat-
egorical data were compared using a χ2 test or Fisher’s
exact test. Continuous variables were compared using a
Student’s t-test, Mann–Whitney U test or Wilcoxon rank-
sum test, as appropriate. All P-values are two-sided and
are not adjusted for multiple comparisons. Time to extu-
bation was plotted using Kaplan-Meier survival analysis,
and differences between groups were compared with the
log-rank test. A Cox proportional hazards analysis was
also performed to assess the impact of both treatment
phase and APACHE II score on the time to extubation.
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Results
A total of 199 patients were included, with 97 patients
in the before phase and 102 in the after phase. The two
groups were well balanced with respect to baseline
demographics, ICU type, reasons for ICU admission and
mechanical ventilation, and severity of illness (Table 1).
Baseline comorbidities were also similar between groups
with the exception of diabetes mellitus, which was more
common in the after group.
Sedative and opioid use and dosing
The percentage of patients receiving midazolam as the
initial sedative was significantly reduced in the before
versus after phase (58% versus 27%, P <0.0001), as was
the percentage of patients receiving a midazolam infu-
sion at any point during their ICU stay (76% versus 48%,
P <0.0001). Among patients receiving a midazolam in-
fusion, the median total dose and infusion rates were
significantly lower in the after phase (Table 2). Dexmede-
tomidine use as the initial sedative significantly increased
in the after phase (2% versus 39%, P <0.0001), as did the
percentage of patients ever receiving a dexmedetomi-
dine infusion during their ICU stay (39% versus 82%,
P <0.0001). Propofol use did not differ significantly be-
tween phases in either the proportion of patients receiving
or the dose administered (Table 2).
A second sedative was used in 56% and 63% of
patients in the before and after phase, respectively, either
as a result of a switch or as an adjunct. Use of second
sedative was most commonly the result of a switch in
sedative agent (78% versus 71%) as opposed to being
used as an adjunct (22% versus 29%) in both the before
and after phases. Choice of second sedative agent did
not differ significantly between phases (Table 2). Among
patients receiving dexmedetomidine as the second agent
(n =67), 63% (n =42, before =22, after =20) initially re-
ceived midazolam and 37% (n =25, before =8, after =17)
initially received propofol. The median time to initiation
of dexmedetomidine as a second agent was 39 (IQR,
15.75 to 80.0) hours. Fentanyl infusions were used to
treat pain in a high percentage of patients in both groups
(98% versus 93%, P =0.171). Median total fentanyl dose
was significantly lower in the after phase (7.85 mg (IQR, 4
to 20.3) versus 4.10 mg (IQR, 2.3 to 14.7), P =0.0019).
Level of sedation and delirium
The median percentage of RASS scores, per patient, at
the goal level of sedation (RASS 0 to −2) was not signifi-
cantly different in the before versus after phase (Table 3).
The median percentage of scores above goal (RASS +1
to +4) was higher in the after phase (5% (IQR 1 to 11)
versus 9.5% (IQR 3 to 19), P =0.001), whereas the percent-
age of scores at a moderate level of sedation (RASS −3)
was significantly reduced (30% (IQR 15 to 43) versus 18%
(IQR 10 to 46), P =0.049). No difference was observed
in the median percentage of scores at deep sedation
(RASS −4 to −5) (Table 3).
The median number of CAM-ICU assessments per
patient was 14 (IQR, 9 to 20) in the before phase and 11
(IQR, 6 to 17) in the after phase (P =0.007). In the be-
fore phase, 10% of the potential CAM-ICU assessments
were not performed, and patients were deemed unasses-
sable for 11% of the evaluations performed. In the after
phase, 7% of the potential CAM-ICU assessments were
not performed, and patients were deemed unassessable
for 18% of the evaluations performed (Table 3). Both the
prevalence (81% versus 93%, P =0.013) and median per-
centage of days with delirium (55% (IQR, 18 to 83) ver-
sus 71% (IQR, 45 to 100), P =0.001) were increased in
the after phase. Antipsychotics were administered to
29% and 30% of patients in the before and after groups,
respectively (P =0.814).
Clinical outcomes
The median duration of mechanical ventilation was
significantly reduced in the after phase (110 (IQR, 59 to
192) hours versus 74.5 (IQR, 42 to 148) hours, P =0.029).
Time to extubation is displayed in Figure 1. In the Cox
proportional hazards analysis of time to extubation, the
treatment phase was significant (HR, 1.42 (95% confidence
interval (CI), 1.06 to 1.90), P =0.019), whereas APACHE II
score was not (HR, 0.95 (95% CI, 0.96 to 1.01), P =0.239).
Significantly fewer patients required tracheostomy in the
after phase (20% versus 9%, P =0.040). There were no sig-
nificant differences between phases in the occurrence of
self-extubation (3% versus 5%, P =0.721) or the need for
reintubation (6% versus 13%, P =0.149).
The median ICU length of stay was 8 days (IQR, 4 to
12) in the before phase and 6 days (IQR, 3 to 11) in the
after phase (P =0.252). Median hospital length of stay
was not different between groups (17 (IQR, 12 to 23)
versus 16.5 (IQR, 10 to 25) days, 0.770). Mortality oc-
curred in eight and nine patients in the before and after
phases, respectively (P =1.0) (Table 4).
Adverse events
At baseline, 55% and 48% of patients in the before and
after phases, respectively, required vasopressor support
(P =0.352). No significant differences were observed
between the before and after phases in the percentage of
patients requiring a vasopressor dose increase (≥5 μg/
min of norepinephrine or ≥50 μg/min of phenylephrine)
or in the occurrence of bradycardia (heart rate <50
beats/min) while the patients were receiving continuous
sedation (Table 5). Significantly fewer patients required
the addition of a vasopressor in the after phase (26% ver-
sus 10%, P =0.003).
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Patients may have been receiving any of the three sed-
atives at the time of a potential adverse event. Table 5
details which sedative was being administered at the
time of the event. With respect to the need for initiation
of or increased dose of a vasopressor and also the
addition of an inotrope, the majority of patients were
Table 1 Patient baseline characteristicsa
Before phase (n =97) After phase (n =102) P-value
Age, yr, median (IQR) 58 (43 to 66) 56 (41 to 64) 0.332
Sex, n (%) 0.372
Male 50 (52%) 59 (58%)
Female 47 (48%) 43 (42%)
Ethnicity, n (%) 0.196
Caucasian 59 (61%) 57 (56%)
African American 33 (34%) 37 (36%)
Other 3 (3%) 0 (0%)
Not documented 2 (2%) 8 (8%)
Weight, kg, median (IQR) 83 (66 to 97) 86 (72 to 102) 0.153
Intensive care unit, n (%)
Surgical/trauma 67 (69%) 61 (60%) 0.173
Medical 30 (31%) 41 (40%)
Reason for ICU admission, n (%)
Surgical 34 (35%) 43 (42%) 0.282
Medical 36 (37%) 40 (39%)
Trauma 27 (28%) 19 (19%)
APACHE II score,b median (IQR) 21 (17–23) 19 (16–24) 0.800
Vasopressor at baseline, n (%) 53 (55%) 49 (48%) 0.352
Reason for mechanical ventilation, n (%)
Postoperative 24 (25%) 17 (17%) 0.803
Chest trauma 9 (9%) 6 (6%)
Pneumonia 11 (11%) 11 (11%)
Severe sepsis 21 (22%) 18 (18%)
Cardiogenic pulmonary edema 3 (3%) 5 (5%)
PE 2 (2%) 3 (3%)
Asthma 6 (6%) 10 (10%)
Cardiac arrest 1 (1%) 1 (1%)
Airway protection 15 (15%) 22 (22%)
ARDS 3 (3%) 6 (6%)
Other 2 (2%) 3 (3%)
Past medical history, n (%)
Hypertension 49 (51%) 54 (53%) 0.732
Cardiac disease 29 (30%) 31 (30%) 0.939
DM 20 (21%) 36 (35%) 0.021
Asthma or COPD 24 (25%) 32 (31%) 0.299
Malignancy 16 (16%) 17 (17%) 0.974
End-stage renal disease 5 (5%) 6 (6%) 1.0
Cirrhosis 2 (2%) 4 (4%) 0.684
Number of spontaneous breathing trials per patient, median (IQR) 3 (1 to 4) 2 (1 to 5) 0.870
aARDS, Acute respiratory distress syndrome; COPD, Chronic obstructive pulmonary disease; DM, Diabetes mellitus; ICU, Intensive care unit; IQR, Interquartile range;
PE, Pulmonary embolism. bModified Acute Physiology and Chronic Health Evaluation (APACHE) II score excludes neurologic assessment.
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receiving midazolam. Bradycardia, however, more com-
monly occurred while patients were receiving propofol
or dexmedetomidine.
Dexmedetomidine failure occurred in a total of 30
(25%) of the 121 patients receiving the agent in either
the before (n =9) or after (n =21) phase. The reasons for
failure were hypotension in 15 patients, inability to
achieve RASS goal in 8 patients, and bradycardia in 7
patients.
Discussion
The results of the present study demonstrate that im-
plementation of a protocol that reduces benzodiazepine
use and targets light sedation can lead to significant
Table 2 Sedative and opioid usage and dosinga
Before (n =97) After (n =102) P-value
Sedative and opioid use
Initial sedative, n (%)
Midazolam 56 (58%) 28 (27%) <0.0001
Propofol 39 (40%) 34 (33%) 0.315
Dexmedetomidine 2 (2%) 40 (39%) <0.0001
Second sedative, n (%)
Midazolam 16 (16%) 17 (17%) 0.834
Propofol 9 (9%) 9 (9%)
Dexmedetomidine 30 (31%) 37 (37%)
Not applicable 42 (43%) 38 (38%)
Received at any time in ICU, n (%)
Midazolam Infusion 74 (76%) 49 (48%) <0.0001
Dexmedetomidine 38 (39%) 83 (82%) <0.0001
Propofol 53 (55%) 49 (48%) 0.396
Fentanyl infusion 97 (98%) 95 (93%) 0.171
Sedative and opioid dosage and duration
Midazolam
Patients receiving, n (%) 76 (76%) 49 (48%)
Total dose, median (mg) 143 (91 to 231) 56 (23 to 137) 0.0001
Infusion duration, hr, median (IQR) 58 (29 to 103) 38 (20 to 104) 0.06
Infusion rate, mg/kg/hr, median (IQR) 0.03 (0.02 to 0.05) 0.02 (0.01 to 0.04) 0.0124
Dexmedetomidine
Patients receiving, n (%) 38 (39%) 84 (82%)
Total dose, mg, median (IQR) 1.8 (0.6 to 3.1) 2.2 (0.6 to 5.0) 0.541
Infusion duration, hr, median (IQR) 36 (29 to 65) 41 (26 to 85) 0.365
Infusion rate, μg/kg/hr, median (IQR) 0.51 (0.35 to 0.82) 0.57 (0.35 to 0.89) 0.921
Propofol
Patients receiving, n (%) 53 (55%) 50 (48%)
Total dose, g, median (IQR) 4.78 (2.03 to 7.27) 3.78 (1.94 to 8.93) 0.797
Infusion duration, hr, median (IQR) 33 (14 to 61) 33 (15 to 54) 0.982
Infusion rate, μg/kg/min, median (IQR) 29 (20 to 42) 29 (28 to 43) 0.981
Fentanyl
Patients receiving, n (%) 97 (98%) 95 (93%)
Total dose, mg, median (IQR) 7.85 (4 to 20.3) 4.10 (2.3 to 14.7) 0.002
Infusion duration, hr, median (IQR) 84 (36 to 147) 54 (33 to 128) 0.078
Infusion rate, μg/kg/hr, median (IQR) 1.5 (0.8 to 2.4) 1.1 (0.6 to 1.7) 0.002
aICU, Intensive care unit; IQR, Interquartile range.
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Table 3 Level of sedation and delirium assessmenta
Outcome Before (n =97) After (n =102) P-value
Level of Sedation
Percentage of RASS scores +4 to +1 5% (1 to 11) 9.5% (3 to 19) 0.001
Percentage of RASS scores +4 0% (0 to 0) 0% (0 to 0)
Percentage of RASS scores +3 0% (0 to 0) 0% (0 to 0)
Percentage of RASS scores +2 0% (0 to 2.7) 2.3% (0 to 5.4)
Percentage of RASS scores +1 3.7% (0.9 to 7.6) 5.3% (1.5 to 12.5)
Percentage of RASS scores 0 to −2 45% (24 to 64) 48% (20 to 68) 0.789
Percentage of RASS scores −3 30% (15 to 43) 18% (10 to 36) 0.049
Percentage of RASS scores −4 to −5 13% (5 to 23) 9% (2 to 24) 0.154
Delirium evaluationb
Number of potential evaluations 1564 1,585
Number of evaluations performed 1,415 (90%) 1,475 (93%)
Number of evaluations NOT performed 149 (10%) 110 (7%)
Number deemed unassessablec 161/1,415 (11%) 262/1,475 (18%)
Number of positive CAM-ICU assessments 693/1,415 (49%) 806/1,475 (55%)
Number of negative CAM-ICU assessments 561/1,415 (40%) 407/1,475 (27%)
Deliriumb
Delirium at any time during ICU 79 (81%) 95 (93%) 0.013
Percentage of days with delirium 55% (18 to 83) 71% (45 to 100) 0.001
Median number of positive CAM-ICU assessments 6 (1.5 to 11) 5.5 (3 to 12.25) 0.312
Received antipsychotic medicationd 28 (29%) 31 (30%) 0.814
aCAM-ICU, Confusion Assessment Method for the intensive care unit; RASS, Richmond Agitation–Sedation Scale. bDelirium was assessed by using the CAM-ICU and
was performed by the bedside nurse once per shift (every 12 hours) during the ICU stay, up to 14 days. cPatients were unassessable if RASS was −4 or −5 at the time
of the evaluation. dIncludes any typical or atypical antipsychotic administered during the ICU stay, up to 14 days. All values reported are either n (%) of patients or
median (IQR).
Figure 1 Duration of mechanical ventilation. Duration of mechanical ventilation was calculated as the time from intubation until successful
removal of the endotracheal tube or after 24 hours of continuous tracheostomy collar in patients requiring tracheostomy. Patients remaining on
mechanical ventilation longer than 14 days were censored after day 14.
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improvements in the time spent at moderate to deep
levels of sedation, the duration of mechanical ventilation,
and the requirement for tracheostomy. These benefits
were observed despite increases in the prevalence and
duration of ICU delirium. Although the primary change
between phases was to favor earlier and more frequent
use of dexmedetomidine, it is important to note that the
sedation protocol allowed use of other sedatives according
to the ICU team’s discretion and incorporated other key
elements from recent pain, agitation and delirium guide-
lines, such as goal-directed analgesia therapy, multidis-
ciplinary involvement, use of validated tools for routine
assessment of sedation and delirium, and daily spontan-
eous breathing trials. This study therefore represents a
valuable assessment of the clinical effectiveness of modify-
ing sedation practices in a real-world setting.
Table 4 Clinical outcomesa
Outcome Before (n =97) After (n =102) P-value
Duration of mechanical ventilation, hr, median (IQR) 110 (59 to 192.3) 74.5 (42.3 to 148) 0.029
ICU length of stay, days, median (IQR) 8 (4 to 12) 6 (3 to 11) 0.252
Hospital length of stay, days, median (IQR) 17 (12 to 23) 16.5 (10 to 25) 0.770
Required reintubation, n (%) 6 (6%) 13 (13%) 0.149
Self-extubation, n (%) 3 (3%) 5 (5%) 0.721
Required tracheostomy, n (%) 19 (20%) 9 (9%) 0.040
Mortality, n (%) 8 (8%) 9 (9%) 1.0
aICU, Intensive care unit; IQR, Interquartile range.
Table 5 Potential adverse effects
Outcome Both phases combined (n =199) Before (n =97) After (n =102) P-valuea
Addition of vasopressor, n (%) 35 25 (26%) 10 (10%) 0.0031
While on midazolam 20 (57%) 16 (16%) 4 (4%)
While on propofol 7 (20%) 7 (7%) 0
While on dexmedetomidine 6 (17%) 2 (2%) 4 (4%)
While receiving multiple sedatives 1 (3%) 0 1 (1%)
While off sedationb 1 (3%) 0 1 (1%)
Increased dose of vasopressor,c n (%) 45 23 (24%) 22 (22%) 0.718
While on midazolam 21 (47%) 17 (18%) 4 (4%)
While on propofol 10 (22%) 4 (4%) 6 (6%)
While on dexmedetomidine 10 (22%) 2 (2%) 8 (8%)
While receiving multiple sedatives 1 (2%) 0 1 (1%)
While off sedationb 3 (7%) 0 3 (3%)
Addition of inotrope, n (%) 9 6 (6%) 3 (3%) 0.151
While on midazolam 5 (56%) 3 (3%) 2 (2%)
While on propofol 3 (33%) 3 (3%) 0
While on dexmedetomidine 1 (1%) 0 1 (1%)
While receiving multiple sedatives 0 0 0
While off sedationb 0 0 0
Heart rate <50 beats/min, n (%) 25 14 (14%) 11 (11%) 0.438
While on midazolam 5 (20%) 4 (4%) 1 (1%)
While on propofol 9 (36%) 6 (6%) 3 (3%)
While on dexmedetomidine 7 (28%) 3 (3%) 4 (4%)
While receiving multiple sedatives 2 (8%) 1 (1%) 1 (1%)
While off sedationb 2 (8%) 0 2 (2%)
aP-value is for the before versus after phase comparison. bPotential adverse effect occurred during a period of time when no continuous sedation was being
administered (for example, during a sedative interruption or patient may have only been receiving analgesia at that time). cIncreased dose was defined as an
increase from baseline dose of ≥5 μg/min of norepinephrine or ≥50 μg/min for phenylephrine.
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The observed shift in sedative use indicates that the
protocol was effective in reducing midazolam use in
favor of early dexmedetomidine as the primary change
in sedation-related practices between phases. In parallel
with the changes in sedative use, a reduction in sedative
assessments at moderate sedation was observed, as well
as a small increase in the percentage of scores above
goal. Although there is additional room for improve-
ment, this represents a positive step toward the goal of
minimizing time spent at moderate to deep levels of sed-
ation. The occurrences of self-extubation and need for
reintubation were infrequent and not statistically different
between groups; however, it should be noted that both
were increased in the after phase, and this study was not
sufficiently powered to assess these differences. Interest-
ingly, although more than 90% of patients in both groups
received a fentanyl infusion for pain, the total dose was
significantly reduced in the after phase. The most likely
explanation is a reduced duration of fentanyl infusion
secondary to reduced time on mechanical ventilation,
although it is possible that the analgesic properties of dex-
medetomidine or perhaps an improved ability to assess
pain in the after phase could also account for some of this
difference. These results are consistent with early random-
ized trials of dexmedetomidine in surgical patients, which
demonstrated reduced opioid doses [8,9]. However, more
recent studies examining long-term dexmedetomidine use
in mixed medical-surgical ICU populations have shown
either no difference [4,6] or increased opioid needs
compared with benzodiazepines [3]. In the latter study,
the authors found that the increased opioid needs were
primarily in patients targeted for deep sedation, and they
proposed that this likely reflected clinicians’ use of fen-
tanyl to achieve deeper sedation.
With respect to potential adverse effects, increased
occurrences of hypotension or bradycardia were not ob-
served between groups, and the percentage of patients
requiring the addition of a vasopressor while on sedative
therapy was actually lower in the after phase. The major-
ity of patients requiring initiation or an increased dose
of vasopressor were receiving midazolam at the time of
the potential adverse effect. In part, this may have been
a result of clinicians choosing to defer the use of propofol
and/or dexmedetomidine while patients remained hypo-
tensive. Bradycardia (HR <50 bpm) more commonly
occurred while patients were receiving propofol or dex-
medetomidine. Dexmedetomidine failure occurred in one
in four patients, with the most common reason being
hypotension. Although the definitions of hypotension and
bradycardia vary among studies, both toxicities have been
well described in randomized trials [3-6]. Taken together,
these findings suggest that clinicians observed hypoten-
sion or bradycardia early and intervened before it reached
a concerning level. Failure to achieve RASS goal occurred
in 7% of patients, which is slightly lower than the
rates of dexmedetomidine discontinuation due to lack
of efficacy in the Dexmedetomidine versus Midazolam
for Continuous Sedation in the Intensive Care Unit
(MIDEX; ClinicalTrials.gov Identifier: NCT00481312) (9%)
and Dexmedetomidine Versus Propofol for Continuous
Sedation in the Intensive Care Unit (PRODEX; Clinical-
Trials.gov Identifier: NCT00479661) (14%) trials [6].
Researchers in multiple studies have reported signifi-
cant improvements in patient outcomes when sedation
is effectively minimized by using various strategies [10-15].
Compared with benzodiazepines, dexmedetomidine has
also been shown to improve clinical outcomes, including
reduced duration of mechanical ventilation [4,6]. In the
present study, a nursing staff-directed sedation protocol
targeting light sedation was the standard of care. Daily
spontaneous breathing trails were also routinely perfor-
med in both the SICU and MICU, and interruption of
sedatives was combined with this in the SICU. Similarly to
the aforementioned studies comparing continuous infu-
sions of dexmedetomidine and midazolam, we found a
significant reduction in time on the ventilator. This find-
ing supports the clinical effectiveness of the protocol and
is striking, considering that 27% of patients in the after
phase still received midazolam as the initial sedative,
which would be expected to reduce between-group dif-
ferences. One important distinction in our study is that
dexmedetomidine was used up front in 39% of patients in
the after phase, whereas in randomized controlled trials of
dexmedetomidine, the study drug was not initiated until
22 to 41 hours after initiation of mechanical ventilation
and prior sedative therapy [3,4]. Delayed initiation of dex-
medetomidine in these trials may reduce possible benefits
because of residual effects of previous sedatives, parti-
cularly prior benzodiazepines. A statistically significant
reduction in ICU length of stay was not found, although
a trend in favor of the after phase can be appreciated.
Individual studies of dexmedetomidine also have not
shown a significant reduction in ICU length of stay [3-6],
although the authors of one meta-analysis reported this
finding [16].
With regard to our hypothesis that reduced midazo-
lam use would lead to reduced prevalence and duration
of delirium, we found the opposite. However, this is not
entirely inconsistent with the available evidence. In one
large study comparing continuous infusions of dexme-
detomidine and midazolam, a significant reduction in the
prevalence and duration of delirium was observed [4].
When compared with continuous lorazepam, the pre-
valence of delirium or coma as a combined endpoint was
reduced; however, when the individual endpoints were
assessed, this difference was found to be primarily a result
of reduced coma [3]. In a subsequent subgroup analysis of
the same study, the daily risk of delirium was found to be
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significantly lower in the dexmedetomidine versus the
lorazepam group [17]. In a randomized pilot study,
Ruokonen and colleagues [5] compared midazolam or
propofol to dexmedetomidine and found that the com-
bined endpoint of CAM-ICU and adverse events of
delirium and confusion were increased in the dexme-
detomidine group (44% versus 25%, P =0.035), whereas
the proportion of positive CAM-ICU assessments was not
different between groups. Finally, in the MIDEX study,
delirium was not routinely assessed with a validated tool
while patients were receiving sedative therapy, although
the trialists reported no difference in a combined endpoint
of neurocognitive adverse events (anxiety, agitation or de-
lirium) between the dexmedetomidine and midazolam
groups [6].
Similarly to earlier studies including comparable pa-
tients [18-22], we found that the overall prevalence of
ICU delirium was very high in the present study. Recent
studies shed greater light into the diagnosis of ICU de-
lirium as it relates to both the level of sedation and its
potential impact on patient outcomes [22,23]. Patel and
colleagues [22] performed a prospective cohort study of
102 adult MICU patients requiring mechanical ventila-
tion and continuous infusion of sedatives in which they
performed CAM-ICU assessments before and for up to
2 hours after a daily interruption of sedatives and analge-
sics. The prevalence of delirium was 89% when assessed
prior to daily interruption, as opposed to 77% when as-
sessed after interruption. Patients with rapidly reversible,
sedation-related delirium had significantly fewer ventilator
days and hospital days than did patients who had delirium
that persisted after 2 hours. Given that all patients in our
present study required continuous sedatives for at least
24 hours and that CAM-ICU assessments were not per-
formed during an interruption of sedative therapy, it is
likely that a percentage of this delirium was sedation-
related and potentially rapidly reversible, which would
explain our findings of reduced duration of mechanical
ventilation despite increased delirium. Similarly, Haenggi
and colleagues [23] found that the prevalence of delirium
(using both CAM-ICU and Intensive Care Delirium
Screening Checklist) was reduced by 22% when patients
with a RASS of −2 or −3 were excluded, suggesting that
the depth of sedation can have a significant influence on
the apparent prevalence of delirium. Notably, we included
all assessments for patients at a RASS of −3 and higher,
consistent with the practice in which the CAM-ICU was
originally validated. Despite the reduction in the median
percentage of scores at a RASS of −3, the prevalence of
delirium was still increased in the after phase. Accordingly,
it would seem unlikely that this is an explanation for the
increased delirium we observed in the after phase. How-
ever, though we observed a reduction in the percentage of
scores at moderate sedation, this does not mean that the
level of sedation was lower at the time CAM-ICU assess-
ments were performed, as sedation was assessed much
more frequently than delirium, which was assessed only
twice daily at fixed time points. In fact, the number of
CAM-ICU evaluations deemed unassessable was higher in
the after phase, suggesting a higher frequency of deep sed-
ation at the time of CAM-ICU assessments. It may thus
still be possible that the level of sedation may have influ-
enced the CAM-ICU assessments and the prevalence of
delirium. Finally, because use of any combination of all
three sedatives was allowed in both phases, it is not pos-
sible in the present before-after open-label trial to truly
discern the relative contribution of each sedative to the
observed prevalence of delirium.
Given that other important outcomes, such as time on
mechanical ventilation, were improved in the after
phase, and no evidence that the increased delirium in
the after phase produced harm, an inference that is po-
tentially just as important to note is that delirium per se,
as measured by CAM-ICU in clinical practice, may not
always reliably predict other important quality and safety
indicators and may not alone be a sufficient basis on
which to change practice. Despite the increased delirium
we identified in our cohort, we have not changed our
practice back to the earlier benzodiazepine-based sed-
ation protocol, given the observed benefits in regard to
other important clinical outcomes. Perhaps production
of sedation-related, rapidly reversible delirium may not
be as negative, as long as it does not result in more pro-
longed ventilation or other adverse events. This requires
further study, given the associations between delirium
and a negative impact on both short- and long-term
outcomes.
This study has several important limitations. First, ra-
ther than one discrete change in drug therapy, this study
assesses the impact of implementing a sedation protocol
that merely favors the early use of dexmedetomidine to
minimize use of midazolam infusions. Use of alternative
sedatives was still allowed in both phases. Additionally,
we provided reeducation of sedation-related principles
to facilitate implementation of the protocol. Therefore, it
is difficult to establish that the observed differences are
due solely to the change in sedative therapy. However,
this approach provides useful insight into the clinical ef-
fectiveness of such a change in an ICU clinical practice,
where the use of multiple sedatives is often necessary.
Second, pain was assessed using an institution-specific
scale for non-communicative patients that has not been
validated, and pain assessments were not collected. How-
ever, frequent assessments of pain and appropriate man-
agement were emphasized in both ICUs, and patients
appeared to be treated aggressively, with over 90% of
patients in both phases receiving continuous infusions
of fentanyl. Third, although all nurses were required
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to complete an online education module and one-to-
one follow-up by clinical nurse specialists dedicated
to the SICU and MICU was provided, CAM-ICU assess-
ments were performed by the bedside nurse and were not
validated by other practitioners. Therefore, it is possible
that some inaccuracy exists related to interrater reliability
and changes in assessments and scoring that may have oc-
curred as the study progressed. Nevertheless, this is repre-
sentative of how delirium is commonly assessed in clinical
practice and thus makes our results more generalizable to
typical ICU environments.
With respect to the assessment of sedative failure, we
chose to focus on the potential failure of dexmedetomi-
dine because (1) a main goal of the protocol was to in-
crease dexmedetomidine use and (2) less is known about
tolerance in a real-world setting. Although we report po-
tential hypotension and bradycardia events for all drugs,
we did not assess for midazolam and propofol failure in
the same way. Finally, this was a before-after study and
was not blinded or randomized, and thus a risk of bias
cannot be eliminated.
Conclusions
This study demonstrates the clinical effects of imple-
menting a sedation protocol aimed at minimizing benzo-
diazepine use in favor of early use of dexmedetomidine
while maintaining other best practices with respect to
pain, agitation and delirium. Despite an increased preva-
lence and duration of delirium, the level of sedation and
duration of mechanical ventilation were improved. Al-
though the impact on duration of mechanical ventilation
was positive and consistent with previous studies, fur-
ther investigation of the impact of CAM-ICU-identified
delirium in the real-world setting is warranted. It is also
important to note that dexmedetomidine intolerance
may occur in one of four patients, owing to lack of effi-
cacy, hypotension or bradycardia.
Key messages
 The new protocol was effective in reducing use of
continuous benzodiazepine infusions and increasing
the use of dexmedetomidine.
 The new protocol resulted in lighter levels of sedation
and reduced duration of mechanical ventilation.
 The new protocol increased the prevalence and
percentage of ICU days with delirium.
 One in four patients may experience lack of efficacy
in achieving desired sedation or intolerance of
dexmedetomidine as a result of hypotension or
bradycardia.
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